Tumor microenvironment models
A tumor is a tissue, not a clump of cancer cells. Co-culture organoid models add back the fibroblasts, immune cells, and vasculature that surround a real tumor, because those cells often decide whether a drug works.
A pure cancer-cell organoid can make a drug look effective that fails in a patient, because it omits the cells the tumor hides behind. Putting the microenvironment back is less elegant and far more predictive, and it is where serious oncology screening is heading.
Why co-culture at all?
Cancer-associated fibroblasts build the dense matrix that blocks drug delivery; immune cells can attack the tumor or be co-opted to protect it; endothelial cells form the leaky vessels that determine what reaches the tissue. None of these appears in a cancer-cell-only model. Reintroducing them recreates the resistance mechanisms that matter, so a screen tests the drug against the tumor's defenses rather than the cancer cell in isolation.19
The cells a tumor hides behind
Cancer-associated fibroblasts (CAFs) are not uniform. At least two functional populations recur across tumor types and behave very differently, which is why a model has to represent both.20
| Population | Location | Role |
|---|---|---|
| Myofibroblastic CAFs (myCAFs) | Adjacent to tumor | High alpha-SMA, deposit dense collagen, stiffen the matrix and block drug penetration |
| Inflammatory CAFs (iCAFs) | Further out in the stroma | Secrete IL-6, LIF, and other cytokines that drive inflammation and immune evasion |
Modeling both lets a screen distinguish a drug that kills cancer cells in a dish from one that can also get past the stroma and the immune shield in a body. The clearest case of stroma defeating therapy is pancreatic cancer.
Frequently asked questions
What is a tumor microenvironment model?
A co-culture organoid that grows cancer cells together with the surrounding fibroblasts, immune cells, and vasculature, so drug testing reflects the tumor's real defenses.
Why not just test the cancer cells?
Because the surrounding cells often determine whether a drug reaches and kills the tumor. A cancer-cell-only model can overstate a drug's effectiveness.
What are CAFs?
Cancer-associated fibroblasts, the connective-tissue cells a tumor recruits. Myofibroblastic CAFs stiffen the matrix and block drugs; inflammatory CAFs secrete cytokines that aid immune evasion.
References
- Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18(7):407-418. doi:10.1038/s41568-018-0007-6. Accessed 2026-06-12.
- Ohlund D, et al. Distinct populations of inflammatory fibroblasts and myofibroblastic cancer-associated fibroblasts in pancreatic cancer. Journal of Experimental Medicine. 2017;214(3):579-596. doi:10.1084/jem.20162024. Accessed 2026-06-12.